ArticleThe journal of headache and pain2026
Gnao1 acts as a gatekeeper to alleviate neuropathic pain by silencing pro-nociceptive signaling cascades.
Article in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeuropathic pain is a debilitating condition with limited effective treatments, highlighting an urgent need for non-opioid analgesic targets. Gαo, encoded by the Gnao1 gene, is an abundant G protein in the nervous system and couples to multiple inhibitory GPCRs, but its role in chronic pain remains poorly understood.
methodsSpatial transcriptomics and bulk RNA-sequencing were performed on the spinal cord and dorsal root ganglia (DRG) of mice following spared nerve injury (SNI). Adeno-associated virus (AAV)-mediated Gnao1 overexpression or knockdown was performed in the spinal cord or DRG, followed by pain behavioral testing using von Frey filaments, acetone evaporation test, and mechanical conflict avoidance (MCA) assay. Microglial activation, neuronal injury, and signaling pathways were examined by immunohistochemistry (IHC), Western blotting (WB), and calcium imaging. In vitro studies used BV2 microglia and primary DRG neurons with lentiviral Gnao1 overexpression and LPS or db-cAMP stimulation.
resultsSpatial transcriptomics revealed that Gnao1 is enriched in the spinal dorsal horn (SDH) and significantly downregulated after SNI. Bulk RNA-seq confirmed Gnao1 downregulation in pain-processing regions (DRG and SDH). IHC showed that its cellular localization shifted from neurons to glial cells. Overexpression of Gnao1 in the spinal cord or DRG markedly alleviated SNI-induced mechanical allodynia, cold hypersensitivity, and pain-related avoidance behaviors. Mechanistically, transcriptomic profiling revealed that Gnao1 overexpression broadly suppressed pro-inflammatory and pro-nociceptive pathways. Experimental validation confirmed that Gnao1 overexpression reduced p38, ERK, and NF-κB phosphorylation, and decreased microglial activation. In primary DRG neurons, Gnao1 overexpression also lowered cAMP levels and suppressed db-cAMP-evoked Ca
conclusionGnao1 acts as a gatekeeper negative regulator of neuropathic pain by silencing distinct pro-nociceptive signaling cascades, and highlights its potential as a non-opioid analgesic target. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.